These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21597262)

  • 1. Fourier transform infrared imaging analysis of cancellous bone in alendronate- and raloxifene-treated osteopenic sheep.
    Calton EF; Macleay J; Boskey AL
    Cells Tissues Organs; 2011; 194(2-4):302-6. PubMed ID: 21597262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential Treatment of Estrogen Deficient, Osteopenic Rats with Alendronate, Parathyroid Hormone (1-34), or Raloxifene Alters Cortical Bone Mineral and Matrix Composition.
    Taylor EA; Donnelly E; Yao X; Johnson ML; Amugongo SK; Kimmel DB; Lane NE
    Calcif Tissue Int; 2020 Mar; 106(3):303-314. PubMed ID: 31784772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
    Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL
    Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the bisphosphonate holiday: a preliminary FTIRI study.
    Boskey AL; Spevak L; Ma Y; Wang H; Bauer DC; Black DM; Schwartz AV
    Osteoporos Int; 2018 Mar; 29(3):699-705. PubMed ID: 29204959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative therapeutic effects of alendronate and alfacalcidol on cancellous and cortical bone mass and mechanical properties in ovariectomized osteopenic rats.
    Iwamoto J; Seki A; Takeda T; Sato Y; Yamada H; Yeh JK
    J Nutr Sci Vitaminol (Tokyo); 2006 Feb; 52(1):1-8. PubMed ID: 16637224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
    Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
    Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model.
    Lee YS; Gupta R; Kwon JT; Cho DC; Seo YJ; Seu SY; Park EK; Han I; Kim CH; Sung JK; Kim KT
    Spine J; 2018 Oct; 18(10):1877-1887. PubMed ID: 29793000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol.
    Bitto A; Burnett BP; Polito F; Marini H; Levy RM; Armbruster MA; Minutoli L; Di Stefano V; Irrera N; Antoci S; Granese R; Squadrito F; Altavilla D
    Br J Pharmacol; 2008 Nov; 155(6):896-905. PubMed ID: 18695641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of raloxifene and alendronate on non-enzymatic collagen cross-links and bone strength in ovariectomized rabbits in sequential treatments after daily human parathyroid hormone (1-34) administration.
    Kimura S; Saito M; Kida Y; Seki A; Isaka Y; Marumo K
    Osteoporos Int; 2017 Mar; 28(3):1109-1119. PubMed ID: 27796444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.
    Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
    Yonsei Med J; 2008 Feb; 49(1):119-28. PubMed ID: 18306478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal evaluation of the effects of alendronate on MRI bone microarchitecture in postmenopausal osteopenic women.
    Folkesson J; Goldenstein J; Carballido-Gamio J; Kazakia G; Burghardt AJ; Rodriguez A; Krug R; de Papp AE; Link TM; Majumdar S
    Bone; 2011 Mar; 48(3):611-21. PubMed ID: 21059422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Gamsjaeger S; Buchinger B; Zoehrer R; Phipps R; Klaushofer K; Paschalis EP
    Bone; 2011 Dec; 49(6):1160-5. PubMed ID: 21893225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate.
    Khan MP; Singh AK; Singh AK; Shrivastava P; Tiwari MC; Nagar GK; Bora HK; Parameswaran V; Sanyal S; Bellare JR; Chattopadhyay N
    J Bone Miner Res; 2016 Mar; 31(3):615-29. PubMed ID: 26391310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women.
    Boskey AL; Spevak L; Weinstein RS
    Osteoporos Int; 2009 May; 20(5):793-800. PubMed ID: 18769963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of serial bone mineral density testing for osteoporosis.
    Crandall C
    J Womens Health Gend Based Med; 2001 Nov; 10(9):887-95. PubMed ID: 11747684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
    Delmas PD
    Bone; 2000 Jul; 27(1):1-3. PubMed ID: 10865202
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of combination treatment with alendronate and raloxifene on skeletal properties in a beagle dog model.
    Allen MR; McNerny E; Aref M; Organ JM; Newman CL; McGowan B; Jang T; Burr DB; Brown DM; Hammond M; Territo PR; Lin C; Persohn S; Jiang L; Riley AA; McCarthy BP; Hutchins GD; Wallace JM
    PLoS One; 2017; 12(8):e0181750. PubMed ID: 28793321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B; San Martin J; Crans G; Pavo I
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
    Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
    J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.